Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN

Aims Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin‐converting enzyme inhibitor (ACE‐I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium‐free, non‐absorbed potassium binder approved for HK treatment. We retrospectivel...

Full description

Saved in:
Bibliographic Details
Published in:ESC Heart Failure 2018-08, Vol.5 (4), p.592-602
Main Authors: Pitt, Bertram, Bakris, George L., Weir, Matthew R., Freeman, Mason W., Lainscak, Mitja, Mayo, Martha R., Garza, Dahlia, Zawadzki, Rezi, Berman, Lance, Bushinsky, David A.
Format: Article
Language:English
Subjects:
Angiotensin II Type 1 Receptor Blockers - administration & dosage
Angiotensin-Converting Enzyme Inhibitors - administration & dosage
Biomarkers - blood
Blood pressure
Diabetes
Diabetic Nephropathies - blood
Diabetic Nephropathies - complications
Diabetic nephropathy
Dose-Response Relationship, Drug
Drug Therapy, Combination
Ejection fraction
Follow-Up Studies
Heart failure
Heart Failure - blood
Heart Failure - complications
Heart Failure - physiopathology
Humans
Hyperkalaemia
Hyperkalemia - blood
Hyperkalemia - drug therapy
Hyperkalemia - etiology
Hypertension
Kidney diseases
Laboratories
Losartan - administration & dosage
Original
Original s
Patiromer
Potassium
Potassium - blood
RAASi
Retrospective Studies
Spironolactone - administration & dosage
Stroke Volume - physiology
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin‐converting enzyme inhibitor (ACE‐I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium‐free, non‐absorbed potassium binder approved for HK treatment. We retrospectively evaluated patiromer's long‐term safety and efficacy in HF patients from AMETHYST‐DN. Methods and results Patients with Type 2 diabetes, CKD, and HK [baseline serum potassium >5.0–5.5 mmol/L (mild) or >5.5–
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.12292